Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity

Stopped Sponsor decision to prematurely stop the study, not linked to any safety concern

Conditions

• Breast Cancer

Interventions

• DRUG: Amcenestrant
• DRUG: Tamoxifen
• DRUG: Amcenestrant-matching placebo
• DRUG: Tamoxifen-matching placebo

Sponsor

Sanofi

Collaborators

• [object Object]
• [object Object]
• [object Object]